Beam Therapeutics Inc (BEAM) - Total Assets
Based on the latest financial reports, Beam Therapeutics Inc (BEAM) holds total assets worth $1.48 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BEAM operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Beam Therapeutics Inc - Total Assets Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See BEAM net asset value for net asset value and shareholders' equity analysis.
Beam Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Beam Therapeutics Inc's total assets of $1.48 Billion consist of 85.7% current assets and 14.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Beam Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Beam Therapeutics Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Beam Therapeutics Inc's current assets represent 85.7% of total assets in 2025, an increase from 84.8% in 2017.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, down from 79.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Beam Therapeutics Inc Competitors by Total Assets
Key competitors of Beam Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Beam Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.99 | 8.81 | 5.27 |
| Quick Ratio | 16.99 | 8.81 | 5.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.19 Billion | $1.11 Billion | $549.28 Million |
Beam Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Beam Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.86 |
| Latest Market Cap to Assets Ratio | 1.77 |
| Asset Growth Rate (YoY) | 34.2% |
| Total Assets | $1.48 Billion |
| Market Capitalization | $2.63 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Beam Therapeutics Inc's assets above their book value (1.77x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Beam Therapeutics Inc's assets grew by 34.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Beam Therapeutics Inc (2017–2025)
The table below shows the annual total assets of Beam Therapeutics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.48 Billion | +34.19% |
| 2024-12-31 | $1.10 Billion | -24.38% |
| 2023-12-31 | $1.46 Billion | +8.79% |
| 2022-12-31 | $1.34 Billion | -9.00% |
| 2021-12-31 | $1.47 Billion | +226.44% |
| 2020-12-31 | $451.68 Million | +189.35% |
| 2019-12-31 | $156.10 Million | -6.53% |
| 2018-12-31 | $167.01 Million | +6853.04% |
| 2017-12-31 | $2.40 Million | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more